Notably, SIRT3 can promote the deacetylation of tau at the posttranslational level, inhibiting pathological tau aggregation, which might be a new disease-modifying strategy for drug discovery and biomarker development in AD [141]. This evidence concerns the gene MAPT and Alzheimer disease.